drugset
drugset / Trial / NCT03071055

Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF

NCT03071055 ↗

Phase 2 Completed 20 enrolled Southeast Clinical Research Associates, LLC Genentech, Inc. · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a 24 week open label study to assess the efficacy of bi-weekly ranibizumab for patients with retinal fluid due to exudative macular degeneration refractory to monthly therapy.

Timeline

Start
2017-10-01
Primary completion
2019-06-03
Completion
2019-06-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Ranibizumab Monoclonal antibody 0.5 mg Intravitreal

Indications

wet macular degeneration